MTI-31

Overview

MTI-31 (LXI-15029) is a potent, orally active and highly selective inhibitor of mTORC1 and mTORC2 . MTI-31 is selective for mTOR ( K d : 0.20 nM) versus PIK3CA, PIK3CB and PIK3G with >5,000 fold selectivity in mTOR binding assays. MTI-31 shows an IC 50 of 39 nM for mTOR in LANCE assay of mTOR substrate phosphorylation with 100 μM ATP. MTI-31 can be used for the research of breast cancer .

Application

Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > mTOR

Product Information

• Catalog No.: HY-126077
• CAS No.: 1567915-38-1
• Molecular Formula: C26H30N6O3
• Molecular Weight: 474.55
• Purity: 99.98%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 0.83 mg/mL (1.75 mM); Clear solution
• Availability: In-stock

Source

Original product source